Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Parameter
Laboratory Tests
Factor VIII (Clotting-based and Chromogenic)
Factor VIII (Clotting-based and Chromogenic)
Related items
Cases : 4
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Analytical Information : 6
Literature Review: Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Literature Review: The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Guidelines : 1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Test Information : 16
The genetic background of haemophilia
The future of haemophilia treatment: beyond the suppletion of factor VIII and IX
Role of gene therapy in the future treatment of haemophilia patients
Potency labelling of extended half-life FVIII and FIX products
Personalising therapy in haemophilia Pharmacokinetic-guided dosing of factor VIII and factor IX concentrates
Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy
Optimizing prophylactic treatment in haemophilia: when to use longer-acting products
New developments in the treatment of haemophilia
New developments in the treatment of haemophilia: implications for laboratory testing
Measurement of Factor VIII inhibitors: Detection, Improvement and Perspectives
Measurement of factor VIII for the diagnosis of haemophilia A
Laboratory monitoring of new hemostatic agents (Long-acting factor concentrates)
Inhibitors in mild or moderate hemophilia A
The detection of Factor VIII Inhibitors with the Nijmegen assay
Clinical features of inhibitors in haemophilia A
Antibodies to blood coagulation factors; immunological background
Quality Issues : 3
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Laboratory Tests : 68
Fibrinolysis: Global Fibrinolytic Capacity (GFC) and Clot Formation and Lysis (CloFAL)
ReoRox G2
Thromboelastography (TEG) & Rotational Thromboelastometry (ROTEM)
Thrombin Generation (Clotting-based, Chromogenic and Fluorogenic)
Prothrombin Fragment 1+2 (F1+2)
Heparin Cofactor II (HCII)
The Bleeding Time (BT)
International Sensitivity Index (ISI) & The International Normalised Ratio (INR)
Reptilase (Batroxobin) Time
Prothrombinase-induced Clotting Test (PiCT)
Protamine Sulphate Neutralisation Test
Ecarin Clotting Time
Heparin Induced Thrombocytopenia (HIT), Anti-Platelet Factor 4 (PF4)
ADAMTS13 activity, antigen and inhibitor
Anti-Xa (Clotting-based and Chromogenic)
Activated Clotting Time (ACT)
Factor V Leiden (F5 Arg506Gln)
Prothrombin (F2) G20210A Mutation
Fibrinolysis: Venous Occlusion Test
Fibrinolysis: Urokinase-type Plasminogen Activator (u-PA)
Fibrinolysis: Thrombin Activatable Fibrinolysis Inhibitor (TAFI)
Fibrinolysis: Tissue-type Plasminogen Activator (t-PA)
Fibrinolysis: Plasminogen Activator Inhibitor Type 1 (PAI-1): Serpin E1
Fibrinolysis: Plasminogen (Plg)
Fibrinolysis: α2-Plasmin Inhibitor
Fibrinolysis: Euglobulin Clot Lysis Time (ECLT)
Fibrinolysis: Fibrinogen Degradation Products (FDP)
Fibrinolysis: D-Dimer
Anticardiolipin (aCL) and Anti-β2-Glycoprotein I (Anti-β2GPI)
Lupus Anticoagulant (LA): Dilute Thromboplastin Inhibition (DTI)
Lupus Anticoagulant (LA): Textarin:Ecarin Ratio and Taipan:Ecarin Ratio
Lupus Anticoagulant (LA): Taipan Venom Time
Lupus Anticoagulant (LA): Silica Clotting Time (SCT)
Lupus Anticoagulant (LA): Kaolin Clotting Time (KCT)
Lupus Anticoagulant (LA): Dilute Russell Viper Venom Time (dRVVT)
Homocysteine (Hcy)
Protein C (ProC) Global Assay
Activated Protein C resistance (APC-R)
Protein S (Clotting-based and Immunological)
Protein C (Clotting-based, Immunological and Chromogenic)
Antithrombin (Chromogenic and Immunological)
Platelet Function: Platelet Procoagulant Activity (PCA)
Platelet Function: Flow Cytometry
Platelet Function: Platelet Nucleotides
Global Thrombosis Test (GTT)
Platelet Function: VerifyNow
Platelet Function: PFA-100/200
Platelet Function: Impedance Platelet Aggregometry
Platelet Function: Light Transmission Aggregometry (LTA)
Von Willebrand Factor Propeptide (VWFpp)
Von Willebrand Factor (VWF) Multimers
Ristocetin-Induced Platelet Agglutination (RIPA)
Von Willebrand Factor Activity (VWF:Act)
Von Willebrand Factor Ristocetin Cofactor (VWF:RCo)
Von Willebrand Collagen Binding (VWF:CB)
Factor VIII Binding (VWF:FVIIIB)
Von Willebrand Factor antigeen (VWF:Ag)
Von Willebrand Factor (VWF) Inhibitor
Factor VIII inhibitor
Factor XIII
Factor IX (Chromogenic)
Factor X Assay (RVV)
Factor Assays APTT-Based (1-Stage)
Factor Assays PT-Based (1-Stage)
Fibrinogen
Thrombin Time (TT)
Activated Partial Thromboplastin Time (APTT)
Prothrombin Time (PT)
Haemostatic Cascade : 6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Factor VIII Inhibitor : 2
Normal pooled plasma
Factor VIII deficient plasma
Clotting factor (VIII, IX, XI and XII) : 5
FVIII antigen
Calibrators VIII IX XI XII
Factor VIII chromogenic methods
Deficient plasma FVIII IX XI XII
Activator VIII IX XI XII
Questions or suggestions?
Clotpedia Support Form
Submit
Success
